DiaMedica Therapeutics Reports First Quarter 2025 Financial Results And Provides Business Highlights
DiaMedica Therapeutics Inc. (DMAC)
Last diamedica therapeutics inc. earnings: 11/13 04:12 pm
Check Earnings Report
Company Research
Source: Business Wire
Conference Call and Webcast May 14 at 8:00 AM Eastern Time / 7:00 AM Central TimeTopline DM199 Preeclampsia Phase 2 Part 1A Proof of Concept Results Expected in Near Term and Phase 2 Part 1B Expected to Initiate in Q3 2025KOL Event Scheduled for May 28, 2025 to Discuss the Disease of Preeclampsia and the Ongoing DM199 Phase 2 Study DesignAcute Ischemic Stroke Phase 2/3 Program Enrollment Progressing as PlannedCash Runway into Q3 2026 MINNEAPOLIS--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for acute ischemic stroke and preeclampsia, today provided a business update and financial results for the quarter ended March 31, 2025. Management will host a conference call Wednesday, May 14, 2025, at 8:00 AM Eastern Time / 7:00 AM Central Time to discuss its business update and first quarter 2025 financial results.Preeclampsia Phase 2 Clinical Developments Parts 1A and BDosing in the Phase 2 Par
Show less
Read more
Impact Snapshot
Event Time:
DMAC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DMAC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DMAC alerts
High impacting DiaMedica Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
DMAC
News
- DiaMedica Therapeutics Provides DM199 Preeclampsia Program Update Following Pre-IND Meeting with FDA [Yahoo! Finance]Yahoo! Finance
- DiaMedica Therapeutics Provides DM199 Preeclampsia Program Update Following Pre-IND Meeting with FDABusiness Wire
- DiaMedica Therapeutics (NASDAQ:DMAC) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.MarketBeat
- DiaMedica signals revised ReMEDy2 trial timeline and expansion cohort completion for DM199 amid cash runway into 2027 [Seeking Alpha]Seeking Alpha
- DiaMedica Therapeutics Inc. (DMAC) Q3 2025 Earnings Call Transcript [Seeking Alpha]Seeking Alpha
DMAC
Earnings
- 11/12/25 - Miss
DMAC
Sec Filings
- 12/18/25 - Form 8-K
- 12/8/25 - Form 4
- 11/25/25 - Form 4
- DMAC's page on the SEC website